Endogenous opiate peptides acting pre-and post-synaptically in the dorsal horn of spinal
cord inhibit transmission of nociceptive stimuli. We transfected neurons of the dorsal root …

We examined the pharmacologic characteristics of herpes simplex virus (HSV) vector-
mediated expression of proenkephalin in the dorsal root ganglion in a rodent model of …

We have constructed recombinant herpes simplex virus type 1 vectors for delivery of genes
to sensory neurons in an attempt to modulate nociception. Delivery of recombinant viruses to …

Objective: Preclinical evidence indicates that gene transfer to the dorsal root ganglion using
replication‐defective herpes simplex virus (HSV)‐based vectors can reduce pain‐related …

Trigeminal neuropathic pain represents a real challenge to therapy because commonly
used drugs are devoid of real beneficial effect or patients frequently become intolerant or …

To evaluate the role of the amygdala in pain modulation and opioid-mediated
antinociception, a recombinant, replication-defective herpes virus carrying the human …

Recombinant herpes simplex virus‐1 encoding the rat preproenkephalin A (HSVLatEnk1)
was generated for driving the expression of preproenkephalin A‐derived peptides in dorsal …

To test the utility of gene therapeutic approaches for the treatment of pain, a recombinant
herpes simplex virus, type 1, has been engineered to contain the cDNA for an opioid peptide …

Some chronic pain syndromes are characterized by episodes of intense burning and
hyperalgesia in localized areas of skin. These sensations are thought to be mediated, at …

The first human trial of gene therapy for chronic pain, a phase 1 study of a nonreplicating
herpes simplex virus (HSV)-based vector engineered to express preproenkephalin in …